Aviptadil is under clinical development by Relief Therapeutics and currently in Phase I for Acute Respiratory Distress Syndrome. According to GlobalData, Phase I drugs for Acute Respiratory Distress Syndrome have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Aviptadil’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Aviptadil overview

Aviptadil is under development for the treatment of pulmonary sarcoidosis, coronavirus disease 2019 (COVID-19) pneumonia, checkpoint inhibitor-induced pneumonitis, chronic berylliosis, non-acute lung injury in coronavirus disease (COVID-19), coronavirus disease (COVID-19) associated acute lung injury,   and Infectious acute respiratory distress syndrome (ARDS) (non-COVID-19-related). The drug candidate is administered through inhalation and intravenous route. Aviptadil is a synthetic analogue of 28 amino acid vasoactive intestinal polypeptide. It acts by targeting VIP receptors Vasoactive Intestinal Polypeptide Receptor 1 and Vasoactive Intestinal Polypeptide Receptor 2. It was also under development for the treatment of idiopathic pulmonary fibrosis, acute lung injury, coronavirus disease 2019 (COVID-19) associated acute respiratory distress syndrome and pulmonary arterial hypertension.

Relief Therapeutics overview

Relief Therapeutics is a biopharmaceutical company that develops and commercializes novel products for rare and ultra-rare diseases. It develops products for rare metabolic disorders, rare pulmonary diseases and rare connective tissue disorders. The company’s pipeline drugs include PKU GOLIKE treats phenylketonuria; ACER-001 for urea cycle disorders and maple syrup urine disease; RLF-OD032 for phenylketonuria; RLF-100 (Aviptadil) treats COVID-19 pulmonary sarcoidosis, infectious acute respiratory distress syndrome, checkpoint inhibitor-induced pneumonitis, chronic berylliosis; NEXODYN for chronic wounds; RLF-TD011 targets epidermolysis bullosa and cutaneous T-cell lymphoma. Relief Therapeutics is headquartered in Geneve, Switzerland.

For a complete picture of Aviptadil’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.